,,ii  #aafth ,,congress  #ast ,session  
,s4 #hja  ,,in ,,the ,,senate ,,of ,,the
 ,,united ,,states  ,march #ad1         
#bjai,ms4 ,cortez ,masto 7for herself1  
,mr4 ,cornyn1 ,mr4 ,carper1 and ,mr4    
,cassidy7 introduced the following bill2
 which was read twice and referred to   
the ,committee on ,finance  ,a ,,bill   
,to amend titles ,,xviii and ,,xix of   
the ,social ,security ,act to provide   
the ,medicare ,payment ,advisory        
,commission and the ,medicaid and ,,chip
 ,payment and ,access ,commission with  
access to certain drug payment          
information1 including certain rebate   
information4  #a4 ,providing the        
,medicare ,payment ,advisory ,commission
 and ,medicaid and ,,chip ,payment and  
,access ,commission with access to      
certain drug payment information1       
including certain rebate information    
7a7 ,access to certain part ,d payment  
data ,section #ahfj;,d-#ae7;f7 of the   
,social ,security ,act 7#db ,u4,s4,c4   
#aciew-#aae7;f77 is amended-- 7#a7 in   

paragraph 7#b7--  7,a7 in subparagraph  
7,a77ii71 by striking and at the end2   
7,b7 in subparagraph 7,b71 by striking  
the period at the end and inserting 2   
and2 and  7,c7 by inserting at the end  
the following new subparagraph3  7,c7 by
 the ,executive ,director of the        
,medicare ,payment ,advisory ,commission
 for purposes of monitoring1 making     
recommendations1 and analysis of the    
program under this title and by the     
,executive ,director of the ,medicaid   
and ,,chip ,payment and ,access         
,commission for purposes of monitoring1 
making recommendations1 and analysis of 
the ,medicaid program established under 
title ,,xix and the ,children's ,health 
,insurance ,program under title ,,xxi4  
2 and  7#b7 by adding at the end the    
following new paragraph3  7#c7          
,additional restrictions on disclosure  
of information ,the ,executive          
,directors described in paragraph       
7#b77;,c7 shall not disclose any of the 
following information disclosed to such 

,executive ,directors or obtained by    
such ,executive ,directors pursuant to  
such paragraph1 with respect to a       
prescription drug plan offered by a     
,,pdp sponsor3  7,a7 ,the specific      
amounts or the identity of the source of
 any rebates1 price concessions1 or     
other forms of direct or indirect       
remuneration under such prescription    
drug plan4  7,b7 ,information submitted 
with the bid submitted under section    
#ahfj;,d-#aa by such ,,pdp sponsor4     
7,c7 ,in the case of such information   
from prescription drug event records1 in
 a form that would not be permitted     
under section #dbc4eje7m7 of title #db1 
,code of ,federal ,regulations1 or any  
successor regulation1 if made by the    
,centers for ,medicare  ,medicaid       
,services4  4  7b7 ,access to certain   
rebate and payment data under ,medicare 
and ,medicaid ,section                  
#aibg7;b77#c77;,d7 of the ,social       
,security ,act 7#db ,u4,s4,c4           
#acifr-#h7;b77#c77;,d77 is amended--    

7#a7 in the matter before clause 7i71 by
 striking subsection 7a77#f77;,a77ii7   
and inserting subsection 7a77#f77;,a72  
7#b7 in clause 7iv71 by striking and at 
the end2  7#c7 in clause 7v71 by        
striking the period at the end and      
inserting 1 and2  7#d7 by inserting     
after clause 7v7 the following new      
clause3  7vi7 to permit the ,executive  
,director of the ,medicare ,payment     
,advisory ,commission and the ,executive
 ,director of the ,medicaid and ,,chip  
,payment and ,access ,commission to     
review the information provided4  2     
7#e7 in the matter at the end1 by       
striking #ahfj;,d-#d7;c77#b77;,e7 and   
inserting #ahfj;,d-#d7;c77#b77;,g72 and 
7#f7 by adding at the end the following 
new sentence3 ,any information disclosed
 to the ,executive ,director of the     
,medicare ,payment ,advisory ,commission
 or the ,executive ,director of the     
,medicaid and ,,chip ,payment and       
,access ,commission pursuant to this    
subparagraph shall not be disclosed by  

either such ,executive ,director in a   
form which discloses the identity of a  
specific manufacturer or wholesaler or  
prices charged for drugs by such        
manufacturer or wholesaler44